As previously identified by our group in Ontario, Canada, only 1 in 4 women with TN and HER2+ breast cancer are assessed by a medical oncologist and receive NAC prior to surgery despite the majority being eligible for NAC per current recommendations [2]. The gene discussed is ERBB2; the disease is breast cancer.